MOTS-c vs SS-31: Mitochondrial Peptide Research Comparison
MOTS-c and SS-31 are often grouped together as mitochondrial peptides, but the mechanisms are different: mtDNA-encoded metabolic signalling versus cardiolipin-targeted inner-membrane stabilization.
MOTS-c and SS-31 both belong in mitochondrial research, but they do different jobs. MOTS-c is encoded in the mitochondrial 12S rRNA region and is studied for AMPK-linked metabolic flexibility, glucose handling, stress-response transcription, and diabetic-model bioenergetics.[1][2] SS-31, also called elamipretide, is a synthetic aromatic-cationic tetrapeptide studied for cardiolipin binding, inner-membrane structure, cristae architecture, and electron-transport-chain efficiency.[3][4]
Fast Comparison: MOTS-c vs SS-31
| Point of comparison | MOTS-c | SS-31 / Elamipretide |
|---|---|---|
| Core identity | 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in mitochondrial 12S rRNA. | Synthetic tetrapeptide often described as D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2. |
| Main research focus | Metabolic stress signalling, AMPK activation, glucose metabolism, and retrograde mitochondria-to-nucleus communication. | Cardiolipin binding, inner-membrane stabilization, mitochondrial ROS modulation, and respiratory-chain architecture. |
| Common model systems | Metabolic-flexibility, skeletal-muscle, beta-cell, diabetic-heart, and aging-stress models. | Mitochondrial dysfunction, cardiomyopathy, kidney injury, skeletal-muscle aging, and membrane/cristae models. |
| Evidence record | Strong preclinical and review literature; one placebo-controlled Phase 2 trial is recruiting (no results posted); no completed late-stage human program establishing clinical use. | Approved in the US as Forzinity (elamipretide) for Barth syndrome under FDA accelerated approval, 19 September 2025. Other indications remain investigational. |
| Regulatory status (October 2026) | Not approved anywhere. FDA advisers voted 7-5-2 in July 2026 to recommend it for the 503A bulks list (non-binding; no final FDA action). Named on the WADA 2027 Prohibited List (S4.4.1). | Forzinity is approved for patients weighing at least 30 kg; continued approval may depend on a confirmatory trial. The developer, Stealth BioTherapeutics, renamed itself Mighty Therapeutics in June 2026. |
| Remy product documentation | MOTS-c 10mg research vial; >99% HPLC line standard. | SS-31 10mg research vial; >99% HPLC line standard. |
What Makes MOTS-c Different?
MOTS-c is unusual because it is encoded inside mitochondrial DNA rather than nuclear DNA. Lee et al. described it in Cell Metabolism as a 16-amino-acid peptide that promotes metabolic homeostasis and insulin sensitivity through a pathway involving folate-cycle modulation, AICAR accumulation, and AMPK activation.[1]
That origin matters. MOTS-c is usually discussed as a stress-responsive metabolic signal: a way mitochondria may communicate with the nucleus under energetic pressure.[2]
The clearest research endpoints are AMPK activity, glucose uptake, insulin-sensitivity markers, oxidative-stress response, beta-cell stress biology, and tissue-specific bioenergetic adaptation. "Mitochondrial support" is too vague for this compound.
What Makes SS-31 Different?
SS-31, also called elamipretide, belongs to the Szeto-Schiller family of mitochondria-targeted peptides. The most common mechanistic description is cardiolipin interaction at the inner mitochondrial membrane, with downstream effects on cristae structure, cytochrome c behavior, and electron-transport-chain efficiency.[3]
A separate biophysical literature describes SS-31 binding lipid bilayers and altering membrane properties. That helps explain why the peptide appears in mitochondrial dysfunction models, not just metabolic-signalling assays.[4]
SS-31 is usually the better match when the endpoint is mitochondrial membrane integrity, cardiolipin, oxidative phosphorylation, ROS generation, or cristae architecture. It is adjacent to MOTS-c, not a duplicate of it.
Evidence Strength and Limits
SS-31 has the larger human record. Elamipretide has been evaluated in settings linked to mitochondrial disease and cardiac or skeletal-muscle endpoints.[3] On 19 September 2025 the FDA granted it accelerated approval, as Forzinity, to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg. The approval rests on knee extensor strength, an intermediate endpoint, and continued approval may depend on a confirmatory trial.[5] In June 2026 the developer, Stealth BioTherapeutics, renamed itself Mighty Therapeutics. Its ReNEW Phase 3 trial in dry age-related macular degeneration is expected to finish in late 2027.[6] The approval covers one indication. It does not validate every SS-31 claim.
MOTS-c has a strong preclinical record, starting with the Cell Metabolism characterization and extending into cardiovascular, aging, metabolic-stress, and diabetes-model literature. Public literature still lacks a completed Phase 2 or Phase 3 program that establishes exogenous MOTS-c as a clinical intervention.[1][2] One placebo-controlled Phase 2a trial is registered: NCT07505745, sponsored by Hudson Biotech, in adults with prediabetes and overweight or obesity. It started in February 2026, plans to enrol 120 people and is recruiting; no results are posted.[7]
MOTS-c is not approved anywhere. In July 2026 the FDA Pharmacy Compounding Advisory Committee voted 7-5-2 to recommend MOTS-c for the 503A bulks list. The vote is non-binding, and the FDA had taken no final action as of 7 October 2026. The FDA peptide reclassification tracker covers the votes.[8] The WADA 2027 Prohibited List, in force from 1 January 2027, names MOTS-c under S4.4.1 (AMPK activators).[9]
The Remy MOTS-c and SS-31 vials are research-use-only catalog items; the SS-31 vial is not the approved Forzinity product. Both appear in the Dubai non-retatrutide research-vial catalog and COA map alongside the other research peptides. Treating them as one generic mitochondrial category hides the main difference: MOTS-c is about metabolic signalling; SS-31 is about mitochondrial membrane biology.
When to Use Each Compound in a Study
MOTS-c belongs in studies asking how a mitochondrial-derived peptide changes metabolic stress signalling. Relevant endpoints include AMPK activation, glucose uptake, gene-expression changes under stress, mitochondrial-to-nuclear signalling, beta-cell senescence markers, or diabetic-model bioenergetics.
SS-31 belongs in studies asking how a peptide changes mitochondrial membrane structure or respiratory efficiency. Relevant endpoints include cardiolipin organization, cristae morphology, oxidative phosphorylation, mitochondrial ROS, cytochrome c behavior, or tissue injury models where mitochondrial membrane integrity is central.
For product-format details, compare the MOTS-c 10mg research vial and SS-31 10mg research vial. For broader background, continue to the standalone MOTS-c research profile, the SS-31 research profile, and the peptide stability guide.
Our Research Standards
This article uses peer-reviewed primary literature and reviews. Product references are limited to research-use format and verification. Read our editorial policy →
Mitochondrial Peptide FAQ
What is the main difference between MOTS-c and SS-31?
MOTS-c is a mitochondrial-derived peptide encoded in mitochondrial 12S rRNA and studied mainly for AMPK-linked metabolic signalling. SS-31 is a synthetic tetrapeptide studied for cardiolipin binding and inner-mitochondrial-membrane stabilization.
Which peptide has stronger translational evidence?
SS-31 has the stronger human record. Elamipretide received FDA accelerated approval as Forzinity for Barth syndrome on 19 September 2025, and it has been studied in other mitochondrial disease and cardiomyopathy programs. MOTS-c has strong preclinical metabolic literature. A Phase 2 trial is recruiting, but no completed late-stage human program establishes clinical use.
Can MOTS-c and SS-31 be treated as interchangeable mitochondrial peptides?
No. MOTS-c is mainly a metabolic-signalling peptide. SS-31 is mainly a cardiolipin- and membrane-targeted mitochondrial peptide. They are used for different questions.
How does Remy Research position MOTS-c and SS-31?
Remy Research lists MOTS-c 10mg and SS-31 10mg as research-use-only lyophilized vials for in-vitro laboratory research. Non-Retatrutide products are supplied at a >99% HPLC line standard.
Sources
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. doi: 10.1016/j.cmet.2015.02.009 · PMID: 25738459 ↵
- The role of mitochondria-derived peptides in cardiovascular and metabolic research. PMC8396025 ↵
- Elamipretide: a review of its structure, mechanism of action, and mitochondrial research context. PMC11816484 ↵
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates membrane properties. PMC7247319 ↵
- U.S. Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 19 September 2025. fda.gov ↵
- Mighty Therapeutics, formerly Stealth BioTherapeutics, announces new name. PR Newswire, 16 June 2026. prnewswire.com ↵
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov NCT07505745 (checked 7 October 2026) ↵
- U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov ↵
- World Anti-Doping Agency. 2027 Prohibited List (published 21 September 2026; in force 1 January 2027). wada-ama.org ↵
For catalog details, see MOTS-c 10mg and SS-31 10mg. For adjacent handling context, read the peptide stability guide.